Xencor INC 8-K filings

NASDAQ
Xencor, Inc. successfully held its 2024 Annual Meeting of Stockholders, electing eight directors, ratifying its independent auditor, and approving executive compensation.
NASDAQ
Xencor will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminates their collaboration agreement.
NASDAQ
Xencor announced its first quarter 2024 financial results, highlighting progress in its clinical programs and the approval of Ultomiris for NMOSD.
NASDAQ
Xencor, a clinical-stage biopharmaceutical company, has appointed Bart Cornelissen as its new Senior Vice President and Chief Financial Officer, effective April 9, 2024.
NASDAQ
Xencor released a corporate overview highlighting clinical data for vudalimab in prostate cancer and progress across its bispecific antibody pipeline.
NASDAQ
Xencor announced its fourth quarter and full year 2023 financial results, highlighting clinical progress with its T-cell engagers and vudalimab, while also reporting a workforce reduction and increased net losses.